The following table sets forth the reconciliations of the numerators and denominators of the Company’s basic and diluted earnings per share (“EPS”) calculations for the three months ended March 31, 2026 and 2025.


	Three Months Ended March 31,
	2026			2025
Numerator:
Net loss attributable to Chemours	$	(29	)	$	(5	)
Denominator:
Weighted-average number of common shares outstanding - basic		150,767,077			149,918,386
Dilutive effect of the Company’s employee compensation plans (1)		—			—
Weighted-average number of common shares outstanding - diluted		150,767,077			149,918,386

Basic (loss) earnings per share of common stock (2)	$	(0.19	)	$	(0.03	)
Diluted (loss) earnings per share of common stock (1) (2)		(0.19	)		(0.03	)

(1)

In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS, as their inclusion would have an anti-dilutive effect. As such, with respect to the measure of diluted EPS, the impact of 819,728 and 491,194 potentially dilutive securities is excluded from the calculation for the three months ended March 31, 2026 and March 31, 2025, respectively.

(2)

Figures may not recalculate exactly due to rounding. Basic and diluted earnings per share are calculated based on unrounded numbers.

The following table sets forth the average number of stock options and performance stock options that were out of the money and, therefore, were not included in the Company’s diluted EPS calculations for the three months ended March 31, 2026 and 2025.


	Three Months Ended March 31,
	2026		2025
Average number of stock options		2,367,331		2,800,240